High expression of PD-L2 and CTLA-4 and low expression of PD-1 in the tumor microenvironment of PMBCL suggest efficacy of immune checkpoint blockade for SCT-ineligible patients or patients with refractory disease. The gene discussed is PDCD1LG2; the disease is neoplasm.